Patents by Inventor Hongkui Deng
Hongkui Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11613735Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.Type: GrantFiled: February 4, 2015Date of Patent: March 28, 2023Assignees: BeiHao Stem Cell and Regenerative Medicine Translational Research Institute, Peking University, Beijing Vitalstar Biotechnology Co., Ltd.Inventors: Hongkui Deng, Yuanyuan Du, Yan Shi, Jun Jia, Jinlin Wang, Chengang Xiang, Nan Song, Jun Xu, Ming Yin
-
Publication number: 20220362387Abstract: Senolytic and anti-inflammatory prodrugs are provided, which are designed from a cytotoxic agent, by chemically modifying the cytotoxic agent to incorporate a site cleavable by SA-?-gal following delivery of the prodrug in vivo, to release the active parent drug. The prodrug includes a galactose-based moiety, which is preferably acetylated, and benzyl oxy carboxy group and a cytotoxic agent moiety. The selenolytic prodrug is used to selectively kill one or more senescent cells and/or reduce an acute or chronic inflammatory response in a subject in need thereof, by administering to the subject therapeutically effective amount of the senolytic prodrugs. The disclosed compositions can be used to reduce one or more symptoms associated with a Senescence-associated disease or disorder or an inflammatory disorder, for example, a virus-mediated inflammation, in a subject.Type: ApplicationFiled: September 24, 2020Publication date: November 17, 2022Inventors: Hongkui Deng, Tuoping Luo, Yusheng Cai, Huanhuan Zhou, Yinhua Zhu, Jingjing Zhao, Jiebin Dong, Honggang Li
-
Publication number: 20220135941Abstract: Provided are compositions for long-term maintenance of functional hepatocytes in culture, a method for improved maintenance of functional hepatocytes in vitro, and functional hepatocytes cultures according to the methods. The culture compositions include at least: one activator of adenylate cyclase, one TGF? inhibitor, one Notch inhibitor, one Wnt inhibitor, and/or one BMP inhibitor. The combinations of compounds are added to any hepatocyte cell culture medium in an effective amount to maintain functional hepatocyte function in vitro, long term. The hepatocytes can be used for in vitro drug research and to model liver disease.Type: ApplicationFiled: February 26, 2019Publication date: May 5, 2022Inventors: Hongkui Deng, Chengang Xiang, Yuanyuan Du
-
Publication number: 20220127580Abstract: A method for inducing non-hepatocytes into hepatocyte-like cells, wherein the non-hepatocytes are induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte expansion culture medium and 2C medium for a sufficient period of time to convert the non-hepatocyte cell into cells with hepatocyte-like properties, are provided. The iHeps induced according to the methods are also provided.Type: ApplicationFiled: February 26, 2019Publication date: April 28, 2022Inventors: Hongkui Deng, Bingqing Xie, Da Sun, Yuanyuan Du
-
Publication number: 20220025321Abstract: Provided are chemical inducers of pluripotency (CIP) which include glycogen synthase kinase inhibitors, TGF? receptor inhibitors, cyclic AMP agonists and S-adenosylhomocysteine hydrolase (SAH) inhibitors or histone acetylators. A method of inducing pluripotency in a partially or completely differentiated cell by using such chemical inducers of pluripotency is also provided. The method includes: (i) contacting a cell with the CIPs for a sufficient period of time to result in reprograming the cell into a pluripotent stem cell having ESC-like characteristics (CiPSC). Isolated chemically induced pluripotent stem cells (CiPSCs) and their progeny, produced by inducing differentiation of the CiPSCs, can be used in a number of applications, including but not limited to cell therapy and tissue engineering.Type: ApplicationFiled: July 22, 2021Publication date: January 27, 2022Inventors: Hongkui Deng, Yang Zhao, Ting Zhao, Jingyang Guan, Xu Zhang, Yao Fu, Junqing Ye
-
Patent number: 11028369Abstract: Factors for extending the ability of isolated pluripotent stem cells to generate extraembryonic lineages in vivo, following in vitro culture, herein, chemical extenders of pluripotency (CEP). Methods of extending the ability of a pluripotent cell to generate embryonic and extraembryonic lineages. The cell to be reprogrammed is contacted with effective amounts of the CEPs for a sufficient period of time to reprogram the cell into a chemically induced extended pluripotent cell (ciEPSC). ciEPSC are identified as an extended pluripotent cell based on properties including: (i) morphologically and (ii) functionally for example, based on their ability contribute to both TE and ICM, in vivo. The ciEPSCs can be cultured or induced to differentiate into cells of a desired type, and used in a number of applications, including but not limited to cell therapy and tissue engineering.Type: GrantFiled: August 12, 2016Date of Patent: June 8, 2021Assignees: Beihao Stem Cell and Regenerative Medicine Research Institute Co., Ltd., Peking University, Hong Guan Ltd.Inventors: Hongkui Deng, Yang Yang, Bei Liu, Jun Xu
-
Patent number: 11002736Abstract: SUSD2 protein is used as a marker in identification, selection or separation of pancreatic internal secretion precursor cells and/or newborn pancreatic internal secretion cells; and a use of an mRNA, for encoding the SUSD2 protein, of a precursor protein as the marker in identification of the pancreatic internal secretion precursor cells and/or the newborn pancreatic internal secretion cells. Analysis of gene expression of pancreatic endoderm cells sourced by induced directional differentiation of human pluripotent stem cells finds the enrichment expression of a SUSD2 gene in the pancreatic internal secretion precursor cells and the newborn pancreatic internal secretion cells. A protein encoded by the SUSD2 gene is a receptor protein on cell membranes. Using the protein as the marker, the identification, the selection or the separation of the pancreatic internal secretion precursor cells and the newborn pancreatic internal secretion cells can be conducted.Type: GrantFiled: August 4, 2015Date of Patent: May 11, 2021Assignees: PEKING UNIVERSITY, PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL, BEIJING RUIPU CHENCHUANG TECHNOLOGY CO., LTD.Inventors: Hongkui Deng, Haisong Liu, Dicong Zhu, Huan Yang, Zhen Liang
-
Patent number: 10857185Abstract: Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGF? receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.Type: GrantFiled: July 1, 2016Date of Patent: December 8, 2020Assignees: Beihao Stem Cell and Regenerative Medicine Research Institutes Co., Ltd., Peking UniversityInventors: Hongkui Deng, Xiang Li, Xiaohan Zuo
-
Publication number: 20200277567Abstract: Provided are chemical inducers of lineage reprogramming (CiLR) which include glycogen synthase kinase inhibitors, TGF? receptor inhibitors, cyclic AMP agonists or histone acetylators. Also provided is a method of inducing lineage reprograming in a partially or completely differentiated cell of a first type into a cell with characteristics of a second and different lineage. The method includes: contacting a cell with the CiLR for a sufficient period of time to result in reprograming the cell into a modified XEN-like cell which is subsequently programmed into a cell with characteristics of a second and different lineage.Type: ApplicationFiled: May 31, 2017Publication date: September 3, 2020Inventors: Hongkui Deng, Xiang Li, Defang Liu, Yantao Ma, Xiaomin Du
-
Publication number: 20190282624Abstract: Provided are chemical inducers of pluripotency (CIP) which include glycogen synthase kinase inhibitors, TGF? receptor inhibitors, cyclic AMP agonists and S-adenosylhomocysteine hydrolase (SAH) inhibitors or histone acetylators. A method of inducing pluripotency in a partially or completely differentiated cell by using such chemical inducers of pluripotency is also provided. The method includes: (i) contacting a cell with the CIPs for a sufficient period of time to result in reprogramming the cell into a pluripotent stem cell having ESC-like characteristics (CiPSC). Isolated chemically induced pluripotent stem cells (CiPSCs) and their progeny, produced by inducing differentiation of the CiPSCs, can be used in a number of applications, including but not limited to cell therapy and tissue engineering.Type: ApplicationFiled: November 30, 2015Publication date: September 19, 2019Inventors: Hongkui Deng, Yang Zhao, Ting Zhao, Jingyang Guan, Xu Zhang, Yao Fu, Junqing Ye
-
Publication number: 20180193386Abstract: Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGF? receptor inhibitors, and BET family bromodomain inhibitors and optionally, a selective inhibitor of ROCK or p38 MAPK. These cocktails are used in a method of inducing neuron-like properties in partially or completely differentiated non-neuronal cells. The method includes contacting cells of a first type (non-neuronal) with the CINPs for a sufficient period of time to result in reprogramming the cell into cells of a second type having neuron-like characteristics (CiNs). Isolated chemically induced neurons (CiNs) can be used in a number of applications, including but not limited to cell therapy.Type: ApplicationFiled: July 1, 2016Publication date: July 12, 2018Inventors: Hongkui DENG, Xiang LI, Xiaohan ZUO
-
Publication number: 20180195046Abstract: Factors for extending the ability of isolated pluripotent stem cells to generate extraembryonic lineages in vivo, following in vitro culture, herein, chemical extenders of pluripotency (CEP). Methods of extending the ability of a pluripotent cell to generate embryonic and extraembryonic lineages. The cell to be reprogrammed is contacted with effective amounts of the CEPs for a sufficient period of time to reprogram the cell into a chemically induced extended pluripotent cell (ciEPSC). ciEPSC are identified as an extended pluripotent cell based on properties including: (i) morphologically and (ii) functionally for example, based on their ability contribute to both TE and ICM, in vivo. The ciEPSCs can be cultured or induced to differentiate into cells of a desired type, and used in a number of applications, including but not limited to cell therapy and tissue engineering.Type: ApplicationFiled: August 12, 2016Publication date: July 12, 2018Inventors: Hongkui Deng, Yang Yang, Bei Liu, Jun Xu
-
Patent number: 9982237Abstract: The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell.Type: GrantFiled: July 10, 2014Date of Patent: May 29, 2018Assignee: Hong Guan, Ltd.Inventors: Hongkui Deng, Yang Zhao, Pingping Hou, Yanqin Li, Xu Zhang, Chun Liu, Jingyang Guan, Honggang Li
-
Publication number: 20170227539Abstract: SUSD2 protein is used as a marker in identification, selection or separation of pancreatic internal secretion precursor cells and/or newborn pancreatic internal secretion cells; and a use of an mRNA, for encoding the SUSD2 protein, of a precursor protein as the marker in identification of the pancreatic internal secretion precursor cells and/or the newborn pancreatic internal secretion cells. Analysis of gene expression of pancreatic endoderm cells sourced by induced directional differentiation of human pluripotent stem cells finds the enrichment expression of a SUSD2 gene in the pancreatic internal secretion precursor cells and the newborn pancreatic internal secretion cells. A protein encoded by the SUSD2 gene is a receptor protein on cell membranes. Using the protein as the marker, the identification, the selection or the separation of the pancreatic internal secretion precursor cells and the newborn pancreatic internal secretion cells can be conducted.Type: ApplicationFiled: August 4, 2015Publication date: August 10, 2017Inventors: Hongkui DENG, Haisong LIU, Dicong ZHU, Huan YANG, Zhen LIANG
-
Publication number: 20170218333Abstract: A method for inducing reprogramming of a cell of a first type which is not a non-hepatocyte (non-hepatocyte cell), into a cell with functional hepatic drug metabolizing and transporting capabilities, is disclosed. The non-hepatocyte is induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte cell culture medium and hepatocyte maturation medium for a sufficient period of time to convert the non-hepatocyte cell into a cell with hepatocyte-like properties. The iHeps induced according to the methods disclosed herein are functional induced hepatocytes (iHeps) in that they express I and II drug-metabolizing enzymes and phase III drug transporters and show superior drug metabolizing activity compared to iHeps obtained by prior art methods. The iHeps thus provide a cell resource for pharmaceutical applications.Type: ApplicationFiled: February 4, 2015Publication date: August 3, 2017Inventors: Hongkui Deng, Yuanyuan Du, Yan Shi, Jun Jia, Jinlin Wang, Chengang Xiang, Nan Song, Jun Xu, Ming Yin
-
Publication number: 20170191038Abstract: Provided is a cocktail of factors for converting/reprogramming non-naïve pluripotent stem cells into TGF? signaling-independent (TSI) naïve induced pluripotent stem cells (iPSCs). Also provided are methods for reprograming a non-naïve PSC into a TSI naïve iPSC by contacting the cell to be reprogrammed with effective amounts of compounds for a sufficient period of time to reprogram the cell into a TSI naïve iPSC.Type: ApplicationFiled: September 18, 2015Publication date: July 6, 2017Inventors: Hongkui DENG, Riguo FANG, Kang LIU, Weifeng YANG
-
Publication number: 20160145581Abstract: The invention provides a composition and a method for inducing pluripotency in non-pluripotent eukaryotic cells. The composition comprises chemical inducers of pluripotency (CIPs) including glycogen synthase kinase (GSK) inhibitors, TGFp receptor inhibitors, cyclic AMP agonists, S-adenosylhomocysteine hydrolase (SAH) inhibitors, and optionally an agent that promotes histone acetylation. The method comprises contacting a cell with the CIPs for a sufficient period of time to reprogram the cell into a pluripotent stem cell.Type: ApplicationFiled: July 10, 2014Publication date: May 26, 2016Inventors: Hongkui Deng, Yang Zhao, Pingping Hou, Yanqin Li, Xu Zhang, Chun Liu, Jingyang Guan, Honggang Li
-
Publication number: 20120190059Abstract: The present invention discloses a method for inducing the differentiation of embryonic stem cells (ESC) or induced pluripotent stem cells (iPS cells) into hepatocytes, a method for inducing the differentiation of embryonic stem cells or induced pluripotent stem cells into hepatic endoderm cells, and a method for inducing the differentiation of embryonic stem cells (ESC) or induced pluripotent stem cells into hepatic progenitor cells. The present invention also provides the hepatocytes, hepatic endoderm cells and hepatic progenitor cells obtained by above methods, and the uses of these cells.Type: ApplicationFiled: July 23, 2010Publication date: July 26, 2012Applicant: BEIJING HUAYUANBOCHUANG TECHNOLOGY CO., LTD.Inventors: Hongkui Deng, Mingxiao Ding, Dongxin Zhao, Song Chen, Zhihua Song
-
Patent number: 7776597Abstract: The present invention provided a simple three-step approach based on the combinational induction with activin A, all-trans retinoic acid and, optionally, other maturation factors which are able to induce embryonic stem cells to differentiate into insulin-producing cells. A kit used to induce embryonic stem cells to differentiate into insulin-producing cells was also provided.Type: GrantFiled: April 14, 2006Date of Patent: August 17, 2010Assignee: Beijing Hua Yuan Bo Chuang Technology LimitedInventors: Hongkui Deng, Mingxiao Ding, Yan Shi, Wei Jiang, Lingling Hou, Fuchou Tang
-
Publication number: 20100093090Abstract: The present invention relates to method or kit for efficient reprogramming of somatic cells.Type: ApplicationFiled: September 28, 2009Publication date: April 15, 2010Applicants: PEKING UNIVERSITY, BEIJING HUA YUAN BO CHUANG TECHNOLOGY CO., LTD.Inventors: HONGKUI DENG, YANG ZHAO, XIAOLEI YIN, QIANG ZHANG, FANGFANG ZHU, HAISONG LIU, WEIFENG YANG, CHENGANG XIANG, HAN QIN